The Structural Genomic Consortium (SGC) announced  today  that  SGC and  Cerep, a worldleading biotechnology company, will enter into a collaboration to develop open access biochemical and cell-based  assays for the discovery of small molecule chemical probes and drug candidates on epigenetic targets. As part of the collaboration, Cerep will open a laboratory in Toronto from which it will offer its screening and profiling services.